

PUBLICATIONS
(Peer Reviewed)

Original Papers

1. **Opal SM**, Pittman DL, Hofeldt F. Testicular sarcoidosis. *American Journal of Medicine* 1979; 66:147-150.
2. **Opal SM**, Cross AS, Gemski P. K antigen and its effect on serum sensitivity of rough *E. coli*. *Infection and Immunity* 1982; 37(3):956- 960.
3. Cross AS, **Opal SM**, Kopecko DJ. Progressive increase in antibiotic resistance of gram-negative bacterial isolates at Walter Reed Hospital, 1976-1980. *Archives of Internal Medicine* 1983; 143:2075-2080.
4. Piziak MV, Woodbury C, Berliner D, Takafuji E, Kirkpatrick J, **Opal SM**, Tramont E. Resistance trends of *Neisseria gonorrhoeae* in the Republic of Korea. *Antimicrobial Agents and Chemotherapy* 1984; 25(1):7-9.
5. Willis SM, **Opal SM**, Fitzpatrick JE. Cytophagic histiocytic panniculitis. *Archives of Dermatology* 1985; 121:910-913.
6. Wilkerson RD, Taylor DC, **Opal SM**, Curl WW. *Nocardia asteroides* sepsis of the knee. *Clinical Orthopedics and Related Research* 1985; 197:206-208.
7. Harpster WH, Gonzales C, and **Opal SM**. Pansinusitis caused by the fungus *Drechslera*. *Otolaryngology - Head and Neck Surgery* 1985; 93(5):683-685.
8. **Opal SM**, Saxon JR. Intracranial infection by *Vibrio alginolyticus* following head injury in salt water. *Journal of Clinical Microbiology* 1986; 23(2):373-374.
9. **Opal SM**, Reller LB, Harrington J, Cannady P. *Aspergillus clavatus* endocarditis occurring on a normal aortic valve following coronary artery surgery. *Reviews of Infectious Diseases*. 1986; 8(5):781-785.
10. Witte MC, **Opal SM**, Gilbert JG, Pluss JL, Thomas DA, Olsen JD, Perry ME. Incidence of fever and bacteremia following transbronchial needle aspiration. *Chest* 1986; 89:85-88.
11. **Opal SM**, Asp A, Cannady P, Morse P, Burton L, Hammer P. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. *Journal of Infectious Diseases* 1986; 153 (3):634-637.
12. Pluss JL, **Opal SM**. Pulmonary sporotrichosis: review of treatment and outcome. *Medicine* 1986; 65:(3)143-153.
13. Mayer KH, **Opal SM**. Antimicrobial therapy in patients with malignancies. *Cancer and Metastasis Reviews* 1987; 5:271-293.
14. Goodwin R, **Opal SM**. Polymicrobial bacteremic pneumonia: A report of three cases

caused by *Staphylococcus aureus* and *Streptococcus pneumoniae*. *American Review of Respiratory Disease*.1987; 136:1005-1006.

15. Medeiros A, Mayer KH, **Opal S**. Plasmid mediated beta-lactamases *The Antimicrobial Newsletter* 1988; 5:(9)61-62.
16. **Opal SM**, Cross AS, and Palmer M, and Alamazon R. Group B Streptococcal infection in infants and adults: Contrasts and Comparisons. *Archives of Internal Medicine* 1988; 146:641-645.
17. **Opal SM**, Cross AS, Gemski P: Survey of purported virulence factors of *E. coli* isolated from human blood, urine, and stool specimens. *European Journal of Clinical Microbiology and Infectious Diseases* 1988; 7:425-428.
18. DeBuono B, Brondum J, Kramer J. Gilbert R, and **Opal S.**: Plasmid serotypic and enterotoxin analysis of *Bacillus cereus* in an outbreak setting. *Journal of Clinical Microbiology*. 1988; 26:1571-1574.
19. **Opal SM**, Johnson A, Cross A., Staphylococcal scalded skin syndrome in two immunocompetent adults caused by exfoliatin B producing *Staphylococcus aureus*. *Journal of Clinical Microbiology* 1988; 26:1283-1286.
20. **Opal SM**, Boyce JM, Medeiros AA, Mayer KH, Lyhte LW. Modification of homogeneous resistance in a methicillin-resistant strain of *Staphylococcus aureus* by acquisition of a beta-lactamase plasmid. *Journal of Antimicrobial Chemotherapy* 1989; 23:315-325.
21. Collins HH, Cross AS, Dobek A, **Opal SM**, McClain JB, Sadoff JC: Oral ciprofloxacin and anti-lipopolysaccharide monoclonal antibody protect neutropenic rats from lethal infection with *Pseudomonas aeruginosa*. *Journal of Infectious Diseases* 1989; 159:1073-1082.
22. **Opal S. M.**, Mayer K. H., Roland R., Brondum J., Heelan J., Lyhte L. A foodborne outbreak of salmonellosis among hospital employees. *American Journal of Infection Control* 1989; 17:141-147.
23. Bradburne M, Ettensohn D, **Opal SM**, McCool D: *Pneumocystis carinii* pneumonia limited to the upper lobes in AIDS. *Thorax* 1989; 44:591-593.
24. DeBuono, B. **Opal**, SM, Sarafian S, Lyhte, LW. Analysis of an outbreak of Penicillinase-producing *Neisseria gonorrhoeae* in Rhode Island, 1987. *Journal of Clinical Microbiology* 1989; 27:2125-2127.
25. Cronan J, Marcello A, Horn D, Robinson, Dorfman G, **Opal S**. Antibiotics and nephrostomy tube care: development of bacteremia (Part 1 and Part 2). *Radiology*1989; 172:1041-1045.
26. Boyce JM, Potter-Bynoe G, **Opal SM**, Dziobek L, Medeiros AA. A common source outbreak of *Staphylococcus epidermidis* infections among patients undergoing open-heart surgery. *Journal of Infectious Diseases* 1990; 161:493-499.
27. **Opal SM**, Cross AS, Gemski P, Lyhte LW. Aerobactin and alpha-hemolysin as potential virulence factors in *E. coli* isolated from human blood, urine, and stool.

Journal of Infectious Diseases 1990; 161:747-749.

28. **Opal SM**, Cross AS, Bodmer MW, Palardy JE, Victor GH, Monoclonal antibody directed against TNF protects neutropenic rats from lethal pseudomonas sepsis. *Journal of Infectious Diseases* 1990; 161:1148-1152.
29. **Opal SM**, Mayer KH, Stenberg M, Blazek J, Mikolich, Dickensheets D, Lyhte LW, Trudel R, Musser JM. Nosocomial colonization of health care workers by endemic multiply resistant bacterial pathogens. *Infection Control and Hospital Epidemiology* 1990; 11:479-485.
30. Neill M.A., **Opal S.M.**, Giusti R.A., White R., Culpepper L., Mayer K.H. Lack of efficacy of ciprofloxacin in preventing gastrointestinal carriage in Salmonellosis. *Annals of Internal Medicine* 1991; 114:195-199.
31. Victor GH, **Opal SM**. Spontaneous bacterial peritonitis: analysis and outcome. *Canadian Journal of Infectious Diseases* 1991; 2(4):147-154.
32. **Opal S.M.**, Cross A.S., Sadoff J.C., Collins H.H., Victor G.H., Palardy J., Bodmer M. The efficacy of anti-LPS and anti-TNF monoclonal antibodies in experimental Pseudomonas sepsis. *Journal of Clinical Investigation* 1991; 88:885-890.
33. Weist P, **Opal SM**, Olds GR, Romulo R. The characteristics of malaria in Rhode Island, 1985-1990. *American Journal of Medicine* 1991; 91:30-36.
34. Heelan J, **Opal SM**, Brissette E. The impact of converting to a biphasic culture medium in the incidence of Pseudobacteremia. *Diagnostic Microbiology and Infectious Diseases* 1992; 15:5-11.
35. Horn D.L., **Opal S.M.** Computer assisted review of antibiotic selection for bacteremia. *Infectious Diseases and Clinical Practice* 1992; 1:169-173.
36. Boyce JM, **Opal SM**, Potter-Bynoe G, LaForge RG, Zervos MJ, Furtado G, Victor G, Medeiros AA. Emergence and nosocomial transmission of ampicillin-resistant enterococci. *Antimicrobial Agents and Chemotherapy* 1992; 36:1032-1039.
37. Kim KS, Was CA, Cross AS, **Opal SM**. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. *Lymphokine and Cytokine Research* 1992; 11:293-298.
38. Cross AS, **Opal SM**, Sadoff J, Palardy JE, Bodmer M. Combination immunotherapy in experimental Pseudomonas sepsis. *Journal of Infectious Diseases* 1993; 167:112-118.
39. Romulo RLC, **Opal SM**, Palardy JE. Efficacy of anti-endotoxin monoclonal antibody alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. *Journal of Infectious Diseases* 1993; 167:126-130.
40. Fisher CJ, **Opal SM**, Dhainaut JF, Stephens S, Zimmerman J, Nightengale P, Harris S. et al. Influence of a murine anti-TNF monoclonal antibody (CB0006) on cytokine levels in patients in sepsis. *Critical Care Medicine* 1993; 21:318-327.

41. Richards MJ, Rittman M, Gilbert TT, **Opal SM**, Debuono B, Neill RJ, Gemski P. An unusually severe foodborne outbreak caused by Staphylococcal enterotoxin A. *Public Health Reports* 1993; 108:765-771.
42. Knaus WA, Harrell FE, Fisher CJ, Jr., Wagner DP, **Opal SM**, Sadoff JC, Hein M, Walawander CA, Conboy K, Grasela JH. The clinical evaluation of new drugs for sepsis: A prospective study design based on survival analysis. *Journal of the American Medical Association* 1993; 270:1233-1241.
43. Boyce JM, **Opal SM**, Potter-Bynoe G, Medeiros AA. Spread of methicillin-resistant *S. aureus* in a hospital after exposure to a health care worker with chronic sinusitis. *Clinical Infectious Diseases* 1993; 17:496-504.
44. Hewlett D, Franchini D, Horn D, Alfalla C, Lue Y, Rodriguez M, Roberto M, Yap R, Dipietro D, Peterson S, Eisenberg H, **Opal S**. An outbreak of multi-drug-resistant tuberculosis at a New York City Hospital. *Morbidity and Mortality Weekly Report* 1993; 42 (22): 427-434.
45. Cross AS, **Opal SM**, Sadoff JC, Gemski P. Choice of bacteria in animal sepsis models. *Infection and Immunity* 1993; 61:2741-2747.
46. Horn DL, Hewlett D, Peterson S, Sabido D, **Opal SM**. RISE- resistant tuberculosis meningitis in an AIDS patient. *Lancet* 1993; 341, 177-178.
47. Fisher CJ, Slotman G, **Opal SM**, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedou DC, Catalano MA. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome. *Critical Care Medicine* 1994; 22:12-21.
48. Fisher CJ, Marra M, Palardy JE, Marchbanks CR, Scott R, **Opal SM**. Bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: A placebo-controlled study. *Critical Care Medicine* 1994; 22:553-558.
49. Pololi LH, Coletta EM, Kern DG, Davis S, Kiessling LS, Garber CE, Entin EJ, **Opal SM**, Rakowski W. Developing a competency-based preventive medicine curriculum for medical schools. *American Journal of Medical Education* 1994; 1:1-28.
50. Bhattacharjee AK, **Opal SM**, Palardy JE, Drabick JJ, Collins H, Taylor R, Cotlon A, Cross AS. Affinity purified *E. coli* J5 LPS-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. *Journal of Infectious Diseases* 1994; 170:622-629.
51. Horn DL, Hewlett D. Jr., Haas WH, Butler WR, Crawford JT, Alfalla C, Tan E, Levine A, Nayak A, Peterson S, **Opal SM**. Superinfection with rifampin-isoniazid-streptomycin-ethambutol (RISE)-resistant tuberculosis in three AIDS patients: Confirmation by polymerase chain reaction fingerprinting. *Annals of Internal Medicine* 1994; 121:115-116.

52. Suitters AJ, Foulkes P, **Opal SM**, Palardy JE, Emtages JS, Rolfe M, Stevens S, Morgan A, Holt A, Chaplin L, Shaw N, Nesbitt AM, Bodmer MW. Differential effect of isotype on efficacy of an anti-TNF-alpha chimaeric antibody in experimental septic shock. *Journal of Experimental Medicine* 1994; 179:849-856.
53. Boyce JM, **Opal SM**, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, Fortna S, Romulo RLC, Medeiros AA. Outbreak of multi-drug resistant *Enterococcus faecium* with transferable van B type vancomycin resistance. *Journal of Clinical Microbiology* 1994; 2:1148-1153.
54. Fisher CJ, Dhainaut J-F, **Opal SM**, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson RW, LaBrecque JF, Knaus WA, Sadoff JC, Recombinant human interleukin-1 receptor antagonist reduces the mortality of patients with sepsis syndrome as a function of disease severity: A randomized double-blind placebo controlled trial. *Journal of the American Medical Association* 1994; 271:1836-1843.
55. **Opal SM**, Marra MN, McKelligan B, Fisher CJ, Palardy JE, Scott R. Relative concentrations of endogenous endotoxin binding proteins in infected body fluids. *Lancet* 1994; 344:429-431
56. Fisher CJ, **Opal SM**, Lowry SF, Sadoff JC, LaBrecque JF, Donovan HC, Lookabaugh JL, Lemki J, Pribble JP, Stroma SC, Vigers GP, Russel DA, Thompson RC. Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. *Circulatory Shock* 1994; 44:1-8.
57. Cross AS, **Opal SM**, Therapeutic intervention in sepsis with antibody to endotoxin: Is there a future? *Journal of Endotoxin Research* 1994; 1(1): 57-69.
58. **Opal SM**. Lessons learned in recent clinical trials for sepsis. *Journal of Endotoxin Research* 1995; 2:221-226.
59. Rice S, Palardy JE, Thornton L, Heintz R, **Opal SM**, Clinical, laboratory and management features of a statewide outbreak of enterovirus meningitis. *Clinical Infectious Diseases* 1995; 20:931-937.
60. Horn DL, Hewlett D, Alfalla C, Pella P, Franchini D, **Opal SM**. Limited tolerance of ofloxacin and PZA prophylaxis in health care workers following exposure to RISE resistant tuberculosis. *Infectious Diseases in Clinical Practice* 1995; 4:219-225.
61. Orange J, Salazar-Mather T, **Opal SM**, Wolf S, Spencer RL, McEwen B, Biron CA. Mechanism of interleukin-12 mediated toxicities during experimental viral infections: role of TNF and glucocorticoids. *Journal of Experimental Medicine* 1995; 181:901-914.
62. Hewlett D, Horn DL, Franchini D, Alfalla C, Peterson S, Pella P, **Opal SM**. Nosocomial infection with multidrug resistant and susceptible tuberculosis in 91 health care workers. *Infectious Disease in Clinical Practice* 1995; 4:389-393
63. Coronado B, Yoburn S, **Opal SM**. Antimicrobial induced D-lactic acidemia

- following a jejunal bypass procedure. *Annals of Internal Medicine* 1995; 122:839-842.
64. **Opal SM**, Palardy JE, Jhung JW, Donsky C, Romulo RLC, Parejo N, Marra MN. Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion Peptide in an experimental model of Pseudomonas sepsis. *Antimicrobial Agents and Chemotherapy* 1995; 39:2813-2815.
 65. **Opal SM**, Fisher CJ. Clinical trials in septic shock. Why did they fail? *Intensivmedizin und Notfallmedizin* 1996; 33:160-166.
 66. Horn DL, **Opal SM**, LoMastro E. Antibiotics, endotoxin and cytokine release, a complex and dynamic process. *Scandinavian Journal of Infectious Diseases* 1996; 101: 9-13.
 67. Horn DL, Hewlett D, Alfalla C, Patel A, Brudney K, Crawford JT, Alland D, Kreiswirth B, **Opal SM**, Peterson S. Clinical experience with rifampin-isoniazid-streptomycin-ethambutol-resistant tuberculosis. *Infectious Diseases in Clinical Practice* 1996; 5:68-72.
 68. Bhattacharjee A, **Opal SM**, Taylor R, Naso R, Semenuk M, Zollinger W, Moran EE, Young L, Hammack C, Sadoff JC, Cross AS. A non-covalent complex vaccine prepared with detoxified E. coli J5 LPS and *Neisseria meningitidis* group B outer membrane protein produces protective antibodies against gram-negative bacteremia. *Journal of Infectious Diseases* 1996; 173:1157-1162.
 69. **Opal SM**, Cross AS, Jhung J, Palardy JE, Parejo N. Potential hazards of combination immunotherapy in the treatment of experimental sepsis. *Journal of Infectious Diseases* 1996; 173:1415-1421.
 70. Meyerhoff A, Renzi R, **Opal SM**. Fatal Clostridial sepsis in a patient with no underlying cause of illness. *Clinical Infectious Diseases* 1996; 20:1066-1067.
 71. Fisher CJ, Jr., Agosti J, **Opal SM**, Lowry S, Sadoff J, Balk R, Abraham E, Schein R, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. *New England Journal of Medicine* 1996; 334:1697-1702.
 72. **Opal SM**, Horn DL, Palardy JE, Parejo N, Jhung, J, Bhattacharjee A, Young L. The in vivo significance of antibiotic-induced endotoxin release in experimental gram-negative sepsis. *Journal of Endotoxin Research*, 1996; 3:245-252.
 73. **Opal SM**, Cross AS. The microbial consequences of anti-mediator therapy. *Sepsis* 1997; 1:59-64.
 74. Dellinger P, **Opal SM**, Rotrosen D, Suffredini AF, Zimmerman J. NIH Conference: The Future of sepsis research: From the bench to bedside. *Chest* 1997; 111:744-753.
 75. **Opal SM**, Fisher CJ, Pribble JP, Dhainaut J-F, Vincent JL, Brase R, Lowry SF,

- Sadoff JC, Slotman, G, Levy H, Balk RA, Shelly MP, Lookabaugh J, Donovan H, LeBreque JF, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. The Confirmatory interleukin-1 receptor antagonist trial in sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. *Critical Care Medicine* 1997; 25:1115-1123.
76. Ruzek MC, Miller AH, **Opal SM**, Pearce BD, Biron CA. Characterization of early cytokine responses and IL-6 dependent pathway of endogenous glucocorticoid induction during murine CMV infection. *Journal of Experimental Medicine* 1997; 185:1185-1192.
77. Orange J, Salazar-Mather TP, **Opal SM**, Biron CA. Mechanisms for virus-induced liver disease: TNF-mediated pathology independent of natural killer and T cells during murine CMV infection. *Journal of Virology* 1997; 71:9248-9258.
78. **Opal SM**, Yu R. Anti-endotoxin strategies for the prevention and treatment of septic shock. *Drugs*. 1998; 55:(4) 497-508.
79. **Opal SM**. The Uncertain Value of the Definition of SIRS. *Chest* 1998; 113 (6) 1442-1443.
80. Horn DL, Zabriskie JB, Austrian R, Cleary PP, Ferretti JJ, Fischetti VA, Gotschlich E, Kaplan EL, McCarty M, **Opal SM**, Roberts RB, Tomasz A, Wachtfogel Y. Why have group A Streptococci remained susceptible to penicillin? Symposium - Rockefeller University, October 7, 1996. *Clinical Infectious Diseases* 1998; 26:1341-1345.
81. **Opal SM**, Wherry J, Grint P. Interleukin-10: Potential benefits and possible risks in clinical infectious diseases practice. *Clinical Infectious Diseases* 1998; 27: 1497-1507.
82. **Opal SM**. Bacterial sepsis. *Scientific American Medicine* 1998; (30): 1-17.
83. **Opal SM**. New Treatment modalities in sepsis. *BioMedical Progress* 1998 1: 52-56.
84. **Opal SM**, Jung J, Keith J., Jr., Palardy JE, Parejo N, Schaub J. Human recombinant interleukin-11 in the treatment of immunocompromised animals with experimental *Pseudomonas aeruginosa* sepsis. *Journal of Infectious Diseases* 1998; 178:1205-1208.
85. **Opal SM**, Jung J, Keith JC, Jr., Goldman SJ, Palardy JE, Parejo N. The additive effects of recombinant human interleukin-11 and granulocyte-colony stimulating factor in experimental gram-negative sepsis. *Blood* 1999; 93: 1-7.
86. **Opal SM**, Scannon, P, Vincent J-L, Carroll S, White M, Palardy JE, Parejo N, Pribble JP, Lemke J. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS binding protein in severe sepsis and septic shock. *Journal of Infectious Diseases* 1999; 180; 1584-1589.
87. **Opal SM**, Cohen J: Clinical gram-positive sepsis: Does it fundamentally differ

- from gram-negative bacterial sepsis. *Critical Care Medicine* 1999; 27: 1608-1616.
88. **Opal SM**, Cross AS. The use of immunocompromised animals in sepsis research. *Sepsis* 1999; 2: 235-242.
 89. **Opal SM**. Endotoxin scavengers for the treatment of sepsis. *Progress in Inflammation Research* 1999; 7: 247-260.
 90. **Opal SM**, Horn DL. The microbiology of sepsis: does the nature of the infecting organism and its treatment affect outcome? *Sepsis* 1999; 3: 51-56
 91. **Opal SM**, Cross AS. Clinical trials for sepsis: past failures and future hopes. *Infectious Disease Clinics of North America* 1999; 3: 285-298.
 92. Cross AS, **Opal**, SM, Bhattacharjee A, Donta S, Peducci P, Furer E, Que J, Cyrz S Jr. Immunotherapy for sepsis: Flawed concept of faulty implementation? *Vaccine* 1999; 17: S13-21.
 93. **Opal SM**, Thijs, L. New therapeutic modalities for sepsis: The role of antithrombin III. *Sepsis* 1999; 3: 153-159.
 94. **Opal SM**, Cross AS, Zabriskie J, Bhattarcharjee A, Visvanathan K, Zabriskie JB. Immunoprophylaxis against bacterial sepsis. *Sepsis* 1999; 3: 225-234.
 95. Luchi M, Morrison DC, **Opal SM**, Yoneda K, Slotman G, Chambers H, Wiesenfeld H, Horn DL. A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. *Journal of Endotoxin Research* 2000; 6: 25-32.
 96. Simpson AJ, **Opal SM**, Prins J, White N, Palardy JE, Parejo N. Antibiotic-induced endotoxin release in the treatment of acute septicemic melioidosis. *Journal of Infectious Diseases* 2000; 181:1014-1019.
 97. **Opal SM**, Keith JC Jr, Palardy JE, Parejo N. Human recombinant interleukin-11 has anti-inflammatory activity but does not exacerbate systemic *Listeria* infection. *Journal of Infectious Diseases* 2000; 181:754-756.
 98. Abraham E, Matthay MA, Dinarello CA, Vincent JL, Cohen J, **Opal SM**, Glauser M, Parsons P, Fisher CJ, Repine J. Consensus Conference Definitions for sepsis, acute lung injury, and ARDS, - time for reevaluation. *Critical Care Medicine* 2000; 28: 232-236.
 99. Horn DL, Morrison DC, **Opal SM**, Silverstein R, Visvanathan K, Zabriskie J. What are the microbial components implicated in the pathogenesis of sepsis? How can we prevent this? *Clinical Infectious Diseases* 2000; 31: 851-858.
 100. **Opal SM**, DePalo V. Anti-inflammatory cytokines. *Chest* 2000; 117:1162-1172.
 101. **Opal SM**. The therapeutic rationale for the use of Antithrombin-III in sepsis. *Critical Care Medicine* 2000; 28: S34-37.

102. **Opal SM.** The phylogenetic relationships between the coagulation system and the inflammatory networks. *Critical Care Medicine* 2000; 28: S77-82.
103. Oleszyna D, **Opal SM**, Prins JM, Horn DL, Speelman P, van Deventer SJM, van der Poll, T. Chemotactic activity of CXC chemokines interleukin-8 (IL-8), growth related oncogene (GRO), and epithelial cell-derived neutrophil activating protein (ENA) 78 in urine patients with urosepsis. *Journal of Infectious Diseases* 2000; 182: 1731-1737.
104. Gluck T, **Opal S**, Alattar-Mantis, J, Weitzel T, Lode H, Scholmerich J. Differences between American and German Medical Students and Physicians in Knowledge of Infectious Diseases. *European Journal of Clinical Microbiology and Infectious Diseases* 2000; 19:868-870.
105. **Opal SM**, Palardy JE, Parejo N, Creasey A. The activity of tissue factor pathway inhibitor in experimental superantigen-induced shock and polymicrobial intra-abdominal sepsis. *Critical Care Medicine* 2001; 29:13-18.
106. **Opal SM**, Sypek JP, Keith JC Jr, Schaub RG, Palardy JE, Parejo NA. Evaluation of the safety of recombinant P-selectin glycoprotein ligand Immunoglobulin G fusion peptide in experimental models of localized and systemic infection. *Shock* 2001; 15(4):285-290.
107. Cross AS, **Opal SM**, Warren SH, Palardy JE, Glaser K, Parejo NA, Bhattacharjee AK. Active immunization with a detoxified *Escherichia coli* J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. *Journal of Infectious Diseases* 2001; 183:1079-86.
108. Florquin S, van den Berg JG, Olszyna DP, Claessen N, **Opal SM**, Weening JJ, van der Poll T. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. *Kidney International* 2001; 59: 2054-2061.
109. **Opal SM**, Morrison DL, Palardy JE, Parejo, N. Lipopolyamines as a therapeutic strategy in experimental Gram-negative bacterial sepsis. *Journal of Endotoxin Research* 2001; 7:35-38.
110. Cohen J, Guyatt G, Angus D, Bernard G, Cook D, Marshall J, **Opal SM**. Clinical trial design and analysis of sepsis studies: Charting a new direction. *Critical Care Medicine* 2001;29: 487-496.
111. Warren BL, Eid A, Singer P, Pillay S, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke H-O, Schindel F, Jurs M, Bone RC, **Opal SM** and the KyberSept trial study group. High-dose antithrombin III in severe sepsis (the KyberSept trial). *Journal of American Medicine Association* 2001; 286:1869-187.
112. DePalo V, Kessler C, **Opal SM**. Success or failure in phase 3 sepsis trials: Comparison of the activated Protein C and antithrombin clinical trials. *Advances in Sepsis* 2001; 1(4):114-125.

113. **Opal SM**, Huber CE. Sepsis. *Scientific American Medicine*. 2001; 30 (7): 1-17.
114. Manalo R, Mirsa H, **Opal SM**. Group A Streptococcal tubo-ovarian abscess: a sexually transmitted disease? *Sexually Transmitted Diseases*. 2002; 29:606-607.
115. **Opal SM**, Huber CE. The Toll-like receptors and their role in septic shock. *Critical Care* 2002; 6:125-136.
116. **Opal SM**, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. *Critical Care Medicine* 2002;30(5S): 325-332.
117. Rublee D, **Opal SM**, Schramm W, Keinecke H-O, Knaub S. Quality of life effects of AT III in sepsis survivors: results from the Kybersept trial. *Critical Care* 2002; 6:249-356.
118. Cross AS, **Opal SM**. A new paradigm for the treatment of sepsis: Is it time to consider combination therapy? *Annals of Internal Medicine* 2003; 138:502-505.
119. Schuster DP, Metzler M, **Opal SM**, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Moldawer LL, Coyne E, Souza S, Pribble J, and the Pafase ARDS Prevention Study Group. Recombinant human platelet-activating factor acetylhydrolase to prevent ARDS in severe sepsis: A multicenter, randomized, controlled clinical trial. *Critical Care Medicine* 2003; 31:1612-1619.
120. **Opal SM**, Jasman R, Palardy JE, Parejo N. The effect of anti-CD14 monoclonal antibody on the clearance of Gram-negative bacteremia. *Critical Care Medicine* 2003; 31: 929-932.
121. **Opal SM**, Keith JC, Jr., Jhung, J, Palardy JE, Parejo N, Marchese E, Maganti V. Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis. *Journal of Infectious Diseases* 2003; 187:70-76.
122. **Opal SM**. The clinical relevance of endotoxin in human sepsis: a critical analysis. *Journal of Endotoxin Research* 2003; 8(6):473-476.
123. **Opal SM**, Glueck T. Endotoxin as a drug target. *Critical Care Medicine* 2003; 31(1 Suppl): 57-64.
124. **Opal SM**, Esmon C. Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. *Critical Care* 2003; 7(1): 23-38.
125. Levy M, Ramsey G, Fink M, Marshall J, Cohen J, Angus D, **Opal SM**, Cook D. the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Critical Care Medicine* 2003; 31(4): 1250-1256.
126. Abraham E, Reinhart K, **Opal SM**, Demeyer I, Doig C, Lopez-Rodriguez A, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. *Journal of the American Medical*

- Association* 2003; 290(2): 238-251.
127. **Opal SM**, Maki D, LaRosa, S, Garber G, Dhainaut JF, Graham D, Freebairn R, Bernard G. Systemic host response to sepsis based upon the infection microorganism and effects of drotrecogin alfa activated. *Clinical Infectious Diseases* 2003; 37:50-58.
 128. Lim Y-P, Bendelja K, **Opal SM**, Palardy, JE, Hixson DC. Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis. *Journal of Infectious Diseases* 2003; 188: 919-926.
 129. **Opal SM**. Clinical trial design and outcomes in patients with severe sepsis: analyzing PROWESS. *Shock* 2003; 20(4): 295-302.
 130. Cross AS, **Opal SM**, Palardy JE, Drabick JJ, Warren HS, Huber C, Cook P, Bhattacharjee AK. Phase I study of detoxified *Escherichia coli* J5 lipopolysaccharide (J5dLPS)/ group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. *Vaccine* 2003;21:4576-4587.
 131. Glueck T, **Opal SM**, Rossaint R, Scholmerich J. Fortschritte in der sepsis. *Intensivmed* 2003; 40:392-402.
 132. **Opal SM**. The link between coagulation and innate immunity in severe sepsis. *Scandinavian Journal of Infectious Diseases* 2003;35:535-544.
 133. Cristofaro P, **Opal S**. The human toll-like receptors as a therapeutic target. *Expert opinion on therapeutic targets*. 2003;7(5):603-612.
 134. **Opal**, SM. Severe sepsis and septic shock: defining the clinical problem. *Scandinavian Journal of Infectious Diseases* 2003;35: 529-534.
 135. **Opal SM**, Laterre P-F, Abraham E, Francois B, Wittebole X, Warren B, Dugernier T, Dhainaut J-F, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Lowry S, Souza S, Pribble J, and the (COMPASS) Investigators. Recombinant human platelet-activating factor acetylhydrolase for the treatment of severe sepsis: Results of a Phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. *Critical Care Medicine* 2004; 32(2):332-341.
 136. Glueck T, **Opal SM**. Advances in sepsis therapy. *Drugs* 2004; 64 (8):837-859.
 137. Reinhart K, Glück T, Ligtenberg J, Tschaikowsky K, Bruining A, Bakker J, **Opal SM**, Axtelle T, Turner T, Souza S, Pribble P. CD14 receptor occupancy in severe sepsis: Results of a Phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14) *Critical Care Medicine* 2004; 32:1100-1108.
 138. **Opal SM**. Unintended bias, clinical trial results, and the post-randomization crossover fallacy. *Critical Care Medicine* 2004;32 (3):874-5
 139. Larosa S, **Opal SM**. Clinical trials of novel anticoagulants for severe sepsis: A tale of three molecules. *Advances in Sepsis* 2004;4(1):17-23.

140. **Opal SM.** The nexus between systemic inflammation and disordered coagulation in sepsis. *Journal of Endotoxin Research* 2004; 10; 125-129.
141. Amaral A, **Opal SM**, Vincent J-L. Coagulation in sepsis. *Intensive Care Medicine* 2004; 30(6):1032-1038.
142. Marshall JC, Foster D, Vincent JL, Cook D, Cohen J, Dellinger P, **Opal SM**, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the Medic trial. *Journal of Infectious Diseases* 2004;190:527-34.
143. Cohen J, Cristofaro P, Carlet J, **Opal SM**. A new system of classification of infection. *Critical Care Medicine* 2004; 32(7):1510-1526
144. Artenstein A, **Opal SM**, Cristofaro P, Palarady JE, Parejo N. Chloroquine attenuates the cytotoxic effects of anthrax lethal factor. *Journal of Infectious Diseases* 2004;190:1655-1660.
145. Cross AS, **Opal SM**, Cook P, Drabick J, Bhattacharjee A. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. *Vaccine* 2004; 22:812-817.
146. Gea-Banacloche JC, **Opal SM**, Jorgensen J, Carcillo JA, Sepkowitz KA, Cordonnier C. Sepsis associated with immunosuppressive medications: An evidence-based review. *Critical Care Medicine* 2004; 32(11):S578-S590.
147. Girard T, **Opal SM**, Ely EW. Insights into severe sepsis in older patients; from epidemiology to evidence-based medicine. *Clinical Infectious Diseases* 2005; 40:719-727.
148. **Opal, SM.** The Concept of PIRO as a new conceptual framework to understand sepsis. *Pediatric Critical Care Medicine* 2005; 6: S55-S60.
149. **Opal SM**, Girard T, Ely EW. The immunopathogenesis of sepsis in the elderly. *Clinical Infectious Diseases* 2005; 41: S504-S512.
150. Artenstein A, **Opal JM**, **Opal SM**, Tramont E, Peter G, Russell P. The role of the United States military in vaccine development: a historical review. *Military Medicine* 2005; 170(4): 3-10.
151. Larosa SP, **Opal SM**. Clinical trial results with TFPI and AT. *Critical Care Clinics* 2005; 21:433-448.
152. **Opal SM**, Artenstein A, Cristofaro PA, Jhung J, Palarady JE, Parejo NA, Lim Y-P. Inter-alpha Inhibitor proteins are endogenous furin inhibitors and are protective in experimental anthrax intoxication. *Infection and Immunity* 2005;73(8):5101-5105.
153. Thompson A, Marshall J, **Opal SM**. Intra-abdominal infections in infants and children: Definitions and descriptions. *Pediatric Critical Care Medicine* 2005; 6:S30-S35.

154. **Opal SM**, Keith J, Cristofaro P, Palardy JE, Parejo N, Harnish D, Jung J. The activity of estrogen receptor pathway selective ligands in experimental models of sepsis and inflammation. *Shock* 2005; 24(6): 535-540.
155. **Opal SM**, Palardy, JE, Chen W, Parejo N, Bhattacharjee A, Cross A. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: Its use with CpG adjuvant and potential mechanisms. *Journal of Infectious Diseases* 2005; 192:2074-2080
156. LaRosa SP, **Opal SM**, Utterback B, Yan B, Helterbrand J, Simpson A, Chaowagul W, White N, Fisher C Jr. Decreased protein C, Protein S, and antithrombin III levels are predictive of poor outcome in Gram-negative sepsis caused by *Burkholderia pseudomallei*. *International Journal of Infectious Diseases* 2006; 10(1):25-31.
157. Kienast J, Juers M, Weidermann CJ, Hoffman JN, Ostermann H, Strauss R, Keinecke H-O, Warren BL, **Opal SM**. Treatment effects of high-dose antithrombin III without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. *Journal of Thrombosis and Hemostasis* 2006; 4: 90-97.
158. Weidermann CJ, Hoffman JN, Juers M, Ostermann H, Kienast J, Breigel J, Strauss R, Kleinecke HO, Warren BL, **Opal SM**. High dose antithrombin III in the treatment of severe sepsis with high risk of death. *Critical Care Medicine* 2006; 34(2): 285-292.
159. Cristofaro P, **Opal SM**. The role of Toll like receptors in infection and immunity: clinical implications. *Drugs* 2006; 66(1):15-29.
160. Kumar A, Paladugu B, Haery C, Kumar A, Symeonides A, Taiberg L, Trenholme G, Sandelski J, **Opal SM**, Goldfarb R, Parillo J. Timing of antibiotic administration in relation to duration of shock is a critical determinant of survival in a murine model of *E. coli* sepsis: association with serum lactate and inflammatory cytokines. *Journal of Infectious Diseases* 2006; 193: 251-258.
161. **Opal S.M.** Cross AS. The use of immunocompromised animals as models for human septic shock. *Shock* 2006; 24 (Suppl 1): 64-71.
162. Hoffman JN, Weidermann CJ, Juers M, , Ostermann H, Keinecke H-O, Kienast J, Brigel J, Strauss R, Warren BL, **Opal SM**. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin *Thrombosis and Hemostasis* 2006; 95:850-856.
163. Cristofaro P, **Opal SM**, Keith J, Palardy JE, Parejo N, Harris H, Jung J. WAY 202196, a selective estrogen receptor beta agonist, protects against death in experimental septic shock. *Critical Care Medicine* 2006; 34(6): 2188-2193.
164. Levi M, **Opal SM**. Coagulation abnormalities in critically ill patients. *Critical Care* 2006;10: 222-228.

165. **Opal SM**, Lim Y-P, E Siryaporn E, Moldawer LL, Pribble JP, Palardy JE, Souza S. Longitudinal studies of Inter-alpha Inhibitor proteins in severely septic patients: A potential clinical marker and mediator of severe sepsis. *Critical Care Medicine* 2007; 35: 387-392
166. LaRosa S, **Opal SM**. Sepsis. *American College of Physicians Medicine*. Infectious Disease. ACP Medicine (Online). 2007; 3: 1-14
167. **Opal SM**. The host response to endotoxin, anti-LPS strategies and the management of severe sepsis. *International Journal of Medical Microbiology* 2007; 297: 365-377.
168. Lutterloh E, **Opal SM**. Antibodies to RAGE as a novel treatment for systemic inflammation: implications for therapy. *Expert Opinion in Pharmacotherapy Care* 2007; 8(9):1193-1196.
169. McCamley MK, Crawford GP, Ravnik M, Žumer S, Artenstein AW, **Opal SM**. Optical detection of anchoring at free and fluid surfaces using a nematic liquid crystal sensor. *Applied Physics Letters* 2007; 91(14): 11-15
170. **Opal SM**. Communal living by bacteria and the pathogenesis of urinary tract infections. *PLoS Medicine* 2007 4(12): 349-353.
171. Lutterloh E, **Opal SM**, Pittman D, Keith JC, Kessimian N, Palardy JE, Parejo N. Inhibition of receptor for advanced glycation end products as a novel treatment strategy in severe sepsis. *Critical Care* 2007; 11(6):122-130
172. Aarts, M-WA, Brun-Buisson C, Cook DJ, Kumar A, **Opal SM**, Rocker G, Smith T, Vincent J-L, Marshall JC. Antibiotic management of suspected nosocomial ICU-acquired infection: Does prolonged empiric therapy improve outcome? *Intensive Care Medicine* 2007; 33:1369-1378.
173. Patrozou E, **Opal SM**. Scurvy masquerading as non-resolving cellulitis. *Internal Medicine Journal* 2008; 38:1-2.
174. Kerby M, Freeman S, Prachanronarong K, Artenstein A, **Opal SM**, Tripathi A. Direct sequence detection of pathogenic H5 human influenza. *Journal of Molecular Diagnostics* 2008; 10(3):225-236.
175. Carlet J, Cohen J, Calandra T, **Opal SM**, Masur H. Sepsis, time to reconsider the concept. *Critical Care Medicine* 2008;36(3):964-967
176. van der Poll T, **Opal SM**. The host-pathogen relationship and the molecular pathogenesis of severe sepsis. *Lancet Infectious Diseases* 2008; 8(1):32-44.
177. Larosa S, **Opal SM**. Experimental therapies for the treatment of severe sepsis and septic shock. *Clinics in Chest Medicine* 2008; 29(4):735-747.
178. Christaki E, **Opal SM**. Is the Mortality Rate for Septic Shock Really Decreasing? *Current Opinion in Critical Care* 2008; 14:580-586.

179. Asad S, **Opal SM**. Quorum sensing and the role of cell to cell communication in pathogenesis of invasive infection. *Critical Care* 2008; 12(6): 236-245.
180. Cinel I, **Opal SM**. Molecular Biology of Inflammation and Sepsis: A Primer. *Critical Care Medicine* 2009 37(1): 291-304.
181. **Opal SM**, Patrozou E. Translational research in sepsis: logical deductive reasoning or “mission impossible”? *Critical Care Medicine* 2009; 37: S10-S15.
182. Laterre P-F, **Opal SM**, Abraham E, LaRosa S, Xie F, Poole L, Wunderink R. Assessment of the recombinant human Tissue Factor Pathway Inhibitor (Tifacogin) in patients with severe community acquired pneumonia. *Critical Care* 2009;13 (R36): 1- 14.
183. Van der Poll T, **Opal SM**. The molecular pathogenesis of pneumococcal pneumonia. *Lancet* 2009;374:1543-1556.
184. Dellinger P, Tamakyo J, Angus D, **Opal SM**, Cupo M, McDermott S, Ducher A, Calandra T, Cohen J. Efficacy and safety of a phospholipid emulsion (GR270773) in gram-negative sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. *Critical Care Medicine* 2009;37(11):2929-2938.
185. McCamley MK, Ravnik S, Artenstein AW, **Opal SM**, Zumer S, Crawford GP. Structural changes and optimization of a nematic based open surface sensor. *Journal of Applied Physics* 2009; 105 (Jun 17): 123504-09.
186. **Opal SM**. The evolution of our understanding of the nature of infection and sepsis. *Critical Care Clinics* 2009; 25:637-663.
187. Vincent J-L, **Opal SM**, Marshall JC. The arguments against the use of APACHE II as entry criteria for sepsis studies. *Critical Care Medicine* 2010; 38(1):283-287.
188. Christaki E, **Opal SM**, Kessian N, Keith JC Jr, Parlady JE, Parejo N. Estrogen receptor beta agonism increases survival in experimentally induced severe sepsis and ameliorates the genomic sepsis signature. *Journal of Infectious Diseases* 2010; 201:1250-1257.
189. Christ-Crain M, **Opal SM**. The role of biomarkers in diagnosis and management of severe community acquired pneumonia. *Critical Care* 2010; 14:203-211.
190. Tidswell M, Tillis W, Larosa S, Lynn M, Whittek AE, Kao R, Wheeler J, **Opal SM**, et al. Phase II trial of eritoran (E5564) an antagonist of endotoxin, in patients with severe sepsis. *Critical Care Medicine* 2010; 38(1): 72-83.
191. Gregory SH, Chen W, Mott S, Palardy JE, Parejo N, Heninger S, Anderson CA, Artenstein AW, **Opal SM**, Cross AS. Detoxified J5 core glycolipid/ outer membrane protein B vaccine protects mice from against lethal respiratory challenge with *Francisella tularensis* SchuS4. *Vaccine* 2010; 28: 2909-2915.
192. Hotchkiss RS and **Opal SM**. Immunotherapy for sepsis: A new approach against an ancient foe. *New England Journal of Medicine*. 2010;363(1):87-89.

193. **Opal SM**, Lim, Y-P, Cristofaro P, Artenstein A, Kessimian N, Palardy JE, Delsesto D, Parejo N, Siryaporn E. Inter-alpha inhibitor proteins as a novel treatment strategy of systemic anthrax infection. *Shock* 2011; 35(1):42-44.
194. Larosa SP, **Opal SM**. Biomarkers: the future. *Critical Care Clinics* 2011;27(2):407-419.
195. Wunderink R, Laterre, P-F, LaRosa SP, van der Poll, T, **Opal SM**. The CAPTIVATE trial of human recombinant tissue factor pathway inhibitor for the treatment of severe community-acquired pneumonia: a multinational phase 3 clinical trial. *American Journal of Respiratory Care and Critical Care Medicine* 2011; 183:1561-1568.
196. Kerby MB, Sarma AA, Patel MS, Artenstein AW, **Opal SM**, Tripathi A. Early in vitro transcription termination of human H5 influenza viral RNA synthesis. *Applied Biochemistry and Biotechnology Journal* 2011; 164:497-513: PMID 21207185
197. LaRosa SP, **Opal SM**. Strategies to treat sepsis: the old and the new. *Clinical Investigation* 2011; 1(2): 195-210.
198. Christaki E, **Opal SM**, Kessian N, Pittman D, Palardy JE, Parejo N. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia. *Shock* 2011;35(5):492-498.
199. Tressel SL, Kaneider NC, Foley C, Simon DJ, Koukos G, Agarwal A, Covic L, **Opal SM**, Kuliopulos A. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. *EMBO Molecular Medicine* 2011; 3:1-15.
200. Kalil A, LaRosa SP, Gogate Y, Lynn M, **Opal SM** and the eritoran sepsis study group. The interaction of disease severity and responsiveness to eritoran and other therapies for severe sepsis. *Shock* 2011; 36(4): 327-331.
201. Artenstein A, **Opal SM**. The pro-protein convertases: The importance of being PC. *New Engl J Med* 2011; 365(26): 2507-2718
202. **Opal SM**. Immunologic alterations and the pathogenesis of organ failure in the ICU. *Semin Resp Crit Care Med* 2011;32(5): 599-580.
203. Christaki E, Anyfanti P, **Opal SM**. Immunomodulation in sepsis revisited. *Expert Reviews in anti-Infective Therapy*. 2011; 9(11): 1-20.
204. McCalla S, Ong C, Sarma A. **Opal SM**, Artenstein A, Tripathi A. A simple method of RNA amplification (SMART). *Journal of Molecular Diagnostics*. 2012 (in press)
205. Artenstein A, **Opal SM**. Current existing and potential novel treatment strategies for systemic anthrax infection. *Clinical Infectious Diseases* 2012; 54(8):1148-1161.
206. Kellum J, Lemaeire N, **Opal SM**. The prevention of acute kidney injury secondary to antibiotics. *Kidney International* 2012; 2(1suppl) 61-65.
207. Ong C, Tai W, Sarma A, **Opal SM**, Artenstein A, Tripathi A. Ligation with Nucleic Acid Sequence Based Amplification (LNASBA). *Journal of Molecular Diagnostics* 2012 (in press)

INVITED EDITORIALS AND JOURNAL AND MONOGRAPH PUBLICATIONS

1. **Opal SM.** Fatal aspergillosis outbreak controlled by strict measures. *Hospital Infection Control* Vol. 14 (4):59-60, 1986.
2. Mayer KH, **Opal SM.** Treatment prospects and vaccine development in AIDS. *Rhode Island Medical Journal* 70:27-33, 1987.
3. Mayer KH, **Opal SM.** Antibiotic resistance complicating nosocomial infections. *Infections in Surgery* 6:661-665, 1987.
4. Mayer KH, **Opal, SM:** Antibiotic resistance: A factor in nosocomial infections. *Infections in Medicine* 4:453-458, 1987.
5. **Opal SM.** Is the decline in autopsy rates bad news for infection control? *Hospital Infection Control* Vol. 14(3): 45-46, 1987.
6. **Opal SM.** Chronic EBV infection and the chronic fatigue syndrome. *Rhode Island Department of Health Disease Bulletin* 23:1-4, 1987.
7. DeBuono B, **Opal SM.** (editors) AIDS: A Guide to Rhode Island Physicians. *Rhode Island Dept of Health Bulletin* September, 1989.
8. Mayer KH, **Opal SM.** Unusual Nosocomial Infections. *Infectious Disease Clinics of North America* 3:883-899, 1989.
9. **Opal SM,** Weist PM, Olds GR. Traveler's diarrhea: methods of prevention and treatment. *Rhode Island Medical Journal* 73:199-206, 1990.
10. Weist PM, **Opal SM,** Olds GR. Malaria: The killer from overseas. *Rhode Island Medical Journal* 73:207-214, 1990.
11. Romulo R, Weist PM, **Opal SM,** Olds GR. Travel to developing countries: pre-departure advice. *Rhode Island Medical Journal* 73:181-188, 1990.
12. **Opal SM.** Infection prevention in neutropenia. *Current Opinion of Infectious Diseases.* 3(2):203-207. 1990.
13. **Opal SM.** Foodborne outbreaks of salmonellosis among hospital employees. *Infectious Diseases Digest* 2:29-30, 1990.
14. Emgushov RT, **Opal SM.** Update of Infectious Diseases - 1990. *Rhode Island Medical Journal* 1990; 73:517-523.
15. **Opal SM.** Prevention of infection in neutropenia. *Current Opinion of Infectious Diseases* 4:359-364, 1991.
16. **Opal SM,** Reflections on the Hippocratic Oath. *Rhode Island Medical Journal*

- 74:553-554, 1991.
17. Abalo T, **Opal SM**, Infection Prevention in neutropenia. *Contemporary Internal Medicine* 5:(11) 32-41, 1993.
 18. Young LS, Bone RC, **Opal SM**, Wenzel RP. New immunotherapeutic strategies against gram-negative infections. *Scientific Symposium Proceedings*. Pragmaton Press, Chicago, 3-8, 1993.
 19. **Opal SM** (Editor). Pathophysiology of Sepsis/Septic Shock monograph, text and slide files. *Triclinica*, New York, New York 1993.
 20. **Opal SM**, Palardy JE, Romulo RLC, Cross AS. Tumor necrosis factor receptor fusion protein in the treatment of experimental *Pseudomonas* sepsis. *Pseudomonas News Letter* 18:5. 1993.
 21. Saniel MC, White M, White F, Castillo T, Superable J, Perez A, Dayrit M, **Opal SM**, Donsky C. Multi-drug resistant typhoid fever in the Philippines: highlights of an outbreak. *Journal of the American Medical Association Supplement* (S.E. Asia) 1994; 10:328-333.
 22. Cross AS, **Opal SM**. Endotoxin's role in gram-negative bacterial infection. *Current Opinion in Infectious Diseases* 8:156-163, 1995.
 23. **Opal SM**. Probing to bone as a diagnostic method in pedal osteomyelitis in diabetic patients. *Journal of Diabetes Care*, September 1996, 1-3.
 24. **Opal SM**. Infectious disease challenges in the 1990's. *Rhode Island Medical Journal* 79:100-105, 1996.
 25. **Opal SM**. Encountering Endotoxins: An Emerging Focus of Therapy. *Monograph for the 7th International Congress for Infectious Diseases*. Oxford Clinical Publications. June 10, 1996.
 26. **Opal SM**. New treatment modalities in sepsis. *Die Gelben Hefte*. 39: 51-58, 1999
 27. **Opal SM**, Cross AS. Bacterial sepsis and septic shock: Introductory comments. *Infectious Disease Clinics of North America* 13:1-2, 1999
 28. Dellinger P, Bernard G, **Opal S**. Tackling the sepsis paradox: where are we today? *Society of Critical Care Medicine Symposium* 11-15, 1999
 29. **Opal SM**, Luchi M. New Developments in the pathophysiology of endotoxin and opportunities for treatment. *Current Opinion in Critical Care* 5: 376-370, 1999
 30. **Opal SM**, Keith JC, Jr. The activity of interleukin-11 in the gastrointestinal tract. *Current Opinion in Critical Care* 6: 2000 6:148-152.
 31. **Opal SM**, Huber C. Interleukin-10 in Critical Illness. *Current Opinion in Infectious Diseases* 2000; 13:(3) 221-226.

32. **Opal SM.** New antimicrobial agents for multidrug-resistant Gram-positive bacterial pathogens. *Current Opinion in Critical Care* 2000;6: 337-344.
33. Dhainaut J-F, Abraham E, Fisher CJ, **Opal SM.** The endothelium an under-recognized organ in critical illness. *Critical Care Medicine* 2002 ;30 (suppl 5): 179-180.
34. Dellinger RP, **Opal SM.** Sepsis reports for the literature. *Sepsis* 2000; 4: 57-62.
35. **Opal SM.** Protein C Levels in Severe Sepsis. *Chest.* 2001; 120(3):699-701
36. Dhainaut J-F, Giroir B, **Opal SM.** Introduction to the second Margaux conference on critical illness and sepsis. *Critical Care Medicine* 29 (suppl 7), S1-S2, 2001
37. **Opal SM.** The Genomic Era and 21st Century Medicine: Its Potential Impact in Sepsis Research. *Sepsis.* 2001; 4:197-199.
38. Artenstein A, Neill M, **Opal SM.** The early recognition and management of infection by agents of bioterrorism. *Rhode Island medical Journal* 2001; 84:19-22.
39. **Opal SM.** The clinical impact of novel anticoagulation strategies in sepsis. *Current Opinion in Critical Care* 2001;13: 544-551 .
40. **Opal SM,** Knaub S, Keinecke H-O. Low dose Heparin and High Dose Antithrombin III in severe sepsis. *Journal of the American Medical Association.* 2002; 287: 448-449.
41. **Opal SM.** Current status and future of clinical trials for innovative therapies for sepsis. *Keio Journal of Medicine* 2001; 50(4):294-295.
42. **Opal SM.** Current status and future of clinical trials for innovative therapies for sepsis. *JAMA-Japan News* 2002; (3) 125-129.
43. **Opal SM.** Insights into the immune dysfunction associated with thermal injury. *Critical Care Medicine.* 2002; 30:1651-1653.
44. Artenstein A, Neill MA, **Opal SM.** Bioterrorism and Physicians. *Medicine & Health Rhode Island Medical Journal* 2001; 85(2): 74-77.
45. **Opal SM.** Signaling: how do cells respond to insult? Sepsis: pathophysiologic insights and current management. *Critical Care Medicine Supplement* 2003 pp 1-8.
46. Vincent J-L, **Opal SM,** Torres A, Bonten, Cohen J, Wunderink R. The PIRO concept: I is for infection. *Critical Care* 2003; 7(3): 252-256.
47. **Opal SM.** Anthrax may be the perfect bioterrorist weapon. *Pharmacy Practice News.* 2003;(11):22-24.
48. Dellinger P, Carlet J, Masur H, Gerlach H, Calandra, T, Cohen J, et al. (Gea-Banacloche J, **Opal SM,** section on sepsis in the immunocompromised host).

- Surviving sepsis campaign guidelines for severe sepsis and septic shock. *Critical Care Medicine* 2004;32:858-73.
49. Calandra T, Cohen J and the international sepsis forum (**Opal SM**, and Marshall J-section leaders). Intra-abdominal infections: Section of the ISF consensus conference on infection definitions in the intensive care unit. *Critical Care Medicine* 2005;33(7):1538-1548.
 50. Artenstein AW, Johnson C, Marbury TC et al (**Opal SM** listed as co investigator). A novel cell culture derived smallpox vaccine in vaccinia-naive adults. *Vaccine* 2005;23:3301-3309.
 51. Marshall JC, Dietch E, Moldawer LL, **Opal SM**, Redl H, van der Poll T. Preclinical models of shock and sepsis: What do they tell us? *Shock* 2006; 24 (Suppl 1): 1-6.
 52. **Opal SM**. Editorial commentary. Coming soon to an ICU near you: Severe primary influenza pneumonia from pandemic swine H1N1 influenza. *Critical Care* 2009; 196 (21/Oct/09)
 53. Marshall J, Abraham E, Adikhari N, Aikawa N, **Opal SM** et al. InFACT: a global critical care research response to H1N1. *Lancet* 2009; DOI:10.1016/S0140-6736(09).
 54. Al Qadi M, Alwan A, **Opal SM**, Cilley B, Silverblatt F. Community acquired pneumonia. *Rhode Island Medical Journal* 2010; 93(7): 196-200.
 55. **Opal SM**. New perspectives on immunomodulatory therapy for bacteremia and sepsis. *International Journal of Antimicrobial Agents* 2010; 36 (Suppl 2): S70-S73. (DOI:10.1016.11.008) published on line Dec. 3, 2010
 56. **Opal SM**, Marshall JC, Angus D. Emerging advances and new paradigms for sepsis management. *Critical Connections* 2011 (July); 1:18-21.
 57. **Opal SM**, Calandra T. Antibiotic usage and resistance: Gaining or losing ground on infections in critically ill patients? *JAMA* 2009;302(21):2367-2368.
 58. **Opal SM**. Endotoxin desynchronizes biological clocks. *Critical Care Medicine* 2010; 38(3):977-978.
 59. Dellinger P, **Opal SM**, Degtyareva M, Felbinger T, Berlot G, Girardis M. The role of immunoglobulins in treatment of septic patients. *Intensive Care Med.* 2011; 37(9):1-4.
 60. **Opal SM**. Endotoxemia before and after surgical repair for congenital heart disease. *American Journal of Respiratory and Critical Care Medicine.* 2011; 184:1-2.

On-Line Publications

1. Cristofaro P, **Opal SM**. Controversies of ID: the use of corticosteroids in sepsis.

MD Consult, November 2003.

2. **Opal SM**, Huber CE. Sepsis. *Scientific American Medicine*. 2003; 32 (10): 1-17.

BOOK AND MONOGRAPH CHAPTERS

1. **Opal SM**. Therapy of bacterial meningitis. In: Conn's Current Therapy. W. B. Saunders Co. Philadelphia, PA. 70-74, 1986.
2. Mayer KH, **Opal SM**: Opportunistic infections in patients with HIV infections. In: Color Atlas of AIDS. Alvin Friedman-Kien (editor). 125-150, 1989.
3. Mayer KH, **Opal SM**, Medeiros AA. Mechanisms of antibiotic resistance. In Principles and Practice of Infectious Diseases, Mandell, Douglas, and Bennett (ed.) 3rd Edition; 218-227, 1989.
4. **Opal SM**. The Treatment of Pyelonephritis. In Conn's Current Therapy. 622-624, 1990.
5. **Opal SM**, Mayer KH, DeBuono B, Infectious Diseases: A Guide to Health Care in Rhode Island. Anagnostou (ed). 55-61, 1988.
6. **Opal SM**. Treatment of pyelonephritis. In Conn's Current Therapy 643-645, 1991.
7. Cross AS, Sadoff JC, **Opal SM**, Bhattacharjee AK, Cryz SJ, Immunotherapy for septic shock: A process-oriented approach, Root and Sande In Contemporary Issues in Infectious Diseases. Root, RK and Sande, MA (Eds) Treatment of Serious Infections in the 1990s. Churchill Livingstone, New York, 77-91, 1991.
8. **Opal SM**. Interleukin-1 receptor antagonist as a therapeutic modality in sepsis. In: Yearbook of Intensive Care and Emergency Medicine. J-L Vincent (ed) Springer-Verlag, Berlin, Germany 107-114, 1993.
9. **Opal SM**, Marra M, Cross AS: Interaction of Bactericidal/ Permeability-Increasing Protein with LPS and experience with animal models of gram-negative infections. In: Mediators of Sepsis. Baumgartner, Calandra and Carlet (ed) Flammarion Publishers, Paris, France, 37-46, 1994.
10. **Opal SM**, Mayer KH, Medeiros, AA. Antibiotic Resistance - Problems in Antimicrobial Therapy. In Textbook of Therapeutic Medicine Cunha (ed), 1996.
11. Mayer KH, **Opal SM**, Medeiros AA. Mechanisms of antibiotic resistance. In Principles and Practice of Infectious Diseases, 4th edition, Mandell, Douglas, Bennett (ed) Churchill Livingstone, New York, pp. 212-225, 1995.
12. Mayer KH, **Opal SM**. Opportunistic infections in AIDS. In: Color Atlas of AIDS, second Edition, Friedman-Kien (ed) W.B. Saunders Company, Philadelphia, Pennsylvania 1996 (p. 9-34).

13. **Opal SM.** Urinary Tract Infections in The Intensive Care Unit. In. Intensive Care Medicine, 3rd edition. JM Rippe, RS Irwin, MP Fink, FB Cerra (ed). Little, Brown and Company, Boston, Massachusetts, 1152-1162, 1996.
14. **Opal SM.** Interleukin-1 receptor antagonist in sepsis. In: Therapeutic Modulation of the Cytokines, CRC Press, London, United Kingdom, M. Bodmer and W. Henderson (ed) 196-219, 1996.
15. **Opal SM,** Fisher CJ, Jr., Pribble J. Treatment of sepsis with Interleukin-1 receptor antagonist: Sepsis: Current Perspectives in Pathophysiology and Therapy. K. Reinhart, K Eyrich, C. Sprans (Eds) Springer-Verlag, Berlin (Vol 18) 1994: p 382-390.
16. **Opal SM,** Fisher CJ, Dhainaut J-F, Bodmer M. Anti-TNF strategies: The CB6 Monoclonal Antibody Sepsis Trial. In: The Immune Consequences of Trauma, Shock and Sepsis - Mechanisms and Therapeutic Approaches. (Eds) E. Faist, A.E. Baue and F.W. Schildberg Pabst Science Publishers, Berlin (Vol. II.2) 1996, 1183-1189.
17. Fisher CJ, **Opal SM,** Marra MN. Bactericidal Permeability- Increasing Protein: A potent naturally occurring anti-endotoxin protein. In: Update in Intensive Care Medicine M. Lamy and L.G. Thijs (editors). Springer-Verlag, Berlin (Vol.16) 339-344, 1994.
18. **Opal SM.** Novel therapeutic agents: Why did they fail? In Yearbook of Intensive Care and Emergency Medicine J-L Vincent (editor), Springer-Verlag, Berlin, pp.425-435, 1995.
19. **Opal SM,** Zinner SH. Sepsis and Bacteremia. In: Atlas of Infectious Diseases. R Fekety and G Mandell (editors). Churchill Livingstone, Philadelphia, PA, 3.1-3.14. 1996.
20. Bhattacharjee A, Cross AS, **Opal SM,** Warren HS, Sadoff JC. New trends in *Escherichia coli* 0111:B4 J5 mutant (Rc chemotype) vaccine development for use in gram-negative bacillary sepsis. In: Novel Therapeutic Strategies in the Treatment of Sepsis. D. Morrison and J Ryan (editors). pp.1-12, 1995.
21. Fisher CJ, **Opal SM,** Lowry SF, LaBrequé JF, Donovan HC, Lookabaugh JL, Lemke J, Pribble JP, Stromatt JC, Vigers GP, Russell DA, Thompson RC. The role of interleukin-1, and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. In Cytokines and Anticytokines. Lesslauer W (editor). pp. 1-8, 1997.
22. Marra MN, **Opal SM,** Scott RW, Seilhamer JJ. The use of bactericidal/ permeability-increasing protein and related proteins as potential therapeutic agents for the treatment of endotoxin- related disorders. In: Novel Therapeutic Strategies in the Treatment of Sepsis. D. Morrison and J. Ryan (editor). pp.33-54, 1995.
23. **Opal SM,** Keith J, Interleukin-11 as a potential therapeutic modality in sepsis. In Yearbook of Intensive Care and Emergency Medicine. J-L Vincent (editor)

pp. 111-118, 1996.

24. **Opal SM**, Abraham E. The use of soluble cytokine receptors and anticytokine antibodies in infectious diseases. In: Cytokines in Infectious Diseases. Van Deuren, Gannon, Griffin, van der Meer (editors) 2000 p.85-92.
25. **Opal SM**. Criticisms of Clinical Trials of Sepsis and Organ Failure. Organ Failure Academy. A. Gullo (editor) Vol. 4, 1996, p. 29-41.
26. Cross AS, Sadoff JC, Gemski P, Jr., **Opal SM**. Selection of bacteria for animal models of sepsis. In. Advances in The Treatment of Radiation Injuries. TJ MacVittie, JF Weiss, D Browne (editors). Elsevier Science Inc., New York. pp. 119-126, 1996.
27. **Opal SM**. Basic elements which control the human immune response. In: Critical Care Medicine. APICE. A. Gullo (editor) Fogliazza Publishers, Milano. 11th edition. 1997 Vol. 11:427-436.
28. **Opal SM**. Splenectomy and Splenic Dysfunction. In: Infectious Diseases. D. Armstrong and J Cohen (editors). Times-Mirror International Publishers, p. 4.7.1-7.4, 1999.
29. **Opal SM**. Urinary Tract Infections. In. Intensive Care Medicine. RS Rippe, FB Cerra, JM Irwin, (editors). 4th Edition 1999, p.1117-1126.
30. **Opal SM**. "Clinical trials in sepsis: lessons learnt." In. Biotechnology Volume 5: Monoclonal antibodies, recombinant proteins, and gene therapy. N. Ney (editor). VCH Publishers, Berlin, Germany, 1999: p. 330-341.
31. **Opal SM**. "Animal Models in Endotoxin Research." In: Endotoxin: Its Role in Health and Disease. D. Morrison, S. Vogel, S. **Opal**, H. Braude, editors. Marcel-Dekker Publishers, 1999 p. 809-816.
32. Brade H, **Opal SM**, Vogel SN, Morrison DC. "The future of endotoxin research." In: Endotoxin: Its Role in Health and Disease. D. Morrison, S. Vogel, S. **Opal**, H. Braude, editors. Marcel-Dekker Publishers, 1999 p. 956-958.
33. **Opal**, SM, Chiu L. "Sepsis and Septicemia" In: Conn's Current Therapy, W.B. Saunders Co., Philadelphia, PA. 1999 p. 64-67.
34. **Opal SM**. Infection control issues with viral hemorrhagic fevers. In: Infectious Diseases. D. Armstrong and J. Cohen (editors). Times-Mirror International Publishers. p. 3.14.2-4, 1999.
35. **Opal SM**. Progress in the development of a vaccine against bacterial sepsis. In: Yearbook of Intensive Care Medicine. J. Marshall, J. Cohen (editors), Springer-Verlag publishers. p. 405-422, 1999.
36. **Opal SM**. The interactions between the coagulation system and the systemic immune response. In: Yearbook of Intensive Care Medicine. J Marshall, J. Cohen (editors), Springer-Verlag publishers. 280-291, 1999.

37. **Opal SM**, Scott D. Endocarditis. In: Practical Cardiology. AH Kahn (editor) 2004 (in press).
38. Cross AS, **Opal SM**. "Interactions with the compromised Host." In: Infection and Immune Responses. (M. Sussman editor) Academic Press Publishers, NY 787-802, 2001.
39. **Opal SM**, Keith JC Jr. Therapeutic applications of Interleukin-11 in systemic inflammatory states. In: Advances in the Treatment of Systemic Inflammation and Sepsis. (Faist, E, Baue G, editors) Springer-Verlag publishers, Berlin, 37-52, 2000.
40. **Opal**, SM. The febrile patient with hypotension. In: Managing Difficult Bacterial Infections Robert Read (editor), Science Press Ltd, London. 55-62, 2000.
41. **Opal SM**, Mayer KH, Medeiros AA. Mechanisms of antibiotic resistance. In: Principles and Practice of Infectious Diseases, 5th edition, Mandell, Douglas, Bennett (ed) W.B.Saunders Company, Philadelphia, PA. 236-253, 2000.
42. **Opal SM**. New Therapies for sepsis. The Regensburg Immunology Congress Proceedings. Pabst Science Publishers 2003.
43. Daly J, **Opal SM**. Urinary Tract Infections in the ICU, In: The management of Infections in the ICU. (Irwin, Cerra, and Rippe editors) Lippincott-Raven Publishers, New York, pp. 407-410, 2000.
44. **Opal SM**, Huber C. The immunopathogenesis of Gram-negative sepsis. In: Sepsis, J-L Vincent, J. Carlet, S. **Opal** (editors), Kluwer Scientific Publishers, Boston, MA, pp. 135-157; 2002.
45. **Opal SM**. Urinary tract infections. In: Intensive Care Medicine, Irwin, Cerra, Rippe (editors), 5th edition Lippincott, Williams and Wilkins, Philadelphia, PA. 2001. pp. 1081-1092.
46. Bhattacharjee A, Cross AS, **Opal SM**. Vaccines against sepsis. In: The Sepsis Text, J-L Vincent, J. Carlet, SM **Opal** (editors), Kluwer Scientific Publishers. Boston, MA, pp.827-836; 2002.
47. **Opal SM**, Keith JC, Jr. Interleukin-11: Potential therapeutic Activity in Systemic Inflammatory States. In: Multiple Organ Failure - Pathophysiology, Prevention, and Therapy. A.E. Baue, E. Faist, D.E. Fry (editors), Springer-Verlag. New York, NY, pp. 539-544, 2000.
48. **Opal SM**. Antibody therapy for sepsis: some lessons learned. Novel Therapeutic Proteins. (K. Dembowski and P Stadler- Editors), Wiley-VCH, New York. pp. 297-310, 2001.
49. **Opal SM**. Clinical trial design and monitoring in severe sepsis interventions. International Congress and Symposium Series (volume 249) 61-72, 2002
50. **Opal SM**, Yap RL. Host microbicidal actions of the innate immune response. In:

- Immunology and Infectious Diseases. (LA Doughty, P Linden, editors), Kluwer Academic Publishers. 2003 pp. 1-18.
51. **Opal SM**, Huber CE. Sepsis. In: Infectious Diseases: A clinician's guide to diagnosis, treatment and prevention. (David C Dale, editor) WebMD Publishing, New York. 2003 pp.77-93.
 52. **Opal SM**, Mederios AA. Mechanisms of Antibiotic Resistance. In: Principles and Practice of Infectious Diseases, 6th edition, Mandell, Douglas, Bennett (ed) W.B.Saunders Company, Philadelphia, PA. p.236-253, 2004.
 53. **Opal SM**. Splenectomy and Splenic Dysfunction. In: Infectious Diseases. 2nd Edition. J Cohen and W. Powderly (editors). Mosby, Times-Mirror International Publishers, Edinburgh, UK p. 1145-1150, 2004.
 54. **Opal SM**. Host responses to infection. In: Infectious Diseases. J Cohen and W. Powderly (editors). Mosby, Times-Mirror International Publishers, Edinburgh, UK, p. 31-52, 2004.
 55. Girard TD, **Opal SM**, Ely EW. Severe sepsis in the elderly: does age really matter? In: Yearbook of Intensive Care Medicine. J-L Vincent (editor), Springer-Verlag publishers. p. 254-262, 2005.
 56. **Opal SM**. The Challenge of emerging infections and progressive antibiotic resistance: Are we losing ground in our ongoing struggle with microbial pathogens? In: Yearbook of Intensive Care Medicine. J-L Vincent (editor), Springer-Verlag publishers, p. 69-86, 2005.
 57. **Opal SM**. Severe sepsis and septic shock. In: Surgery: Basic Science and Clinical Evidence 2nd edition. (JA Norton, P Barrie, RR Bollinger, AE Chang, SF Lowry, SJ Mulvihill, HI Pass, RW Thompson-editors). Springer-Verlag Publishers, New York 2008 p. 287-304.
 58. **Opal SM**, Cross AS. The therapeutic rationale of combination immunotherapy for sepsis. In: Anesthesia, Pain, Intensive Care and Emergency Medicine. Volume 20, (Gullo A, editor) Springer-Verlag publishers, Berlin, chapter 44; p. 520-533, 2005.
 59. **Opal SM**, Cristofaro P. Cell signaling pathways of the innate immune system during inflammation. Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (volume 44). JL Vincent, E Abraham, M Singer, editors) Springer Publishers NY; p 35-53. 2006
 60. **Opal SM**. Blood endotoxin and cytokine detection systems as biomarkers for sepsis-induced acute renal injury. In: Acute Kidney Injury in the Critically ill: (Ronco E) – editor: Karger Publishers, Basel CH. Vol. 156, pp 220-226, 2007
 61. **Opal SM**, van der Poll T. Pathophysiology of sepsis. In: Early Diagnosis of Sepsis. (Dellinger P, Carlet J editors). Biomelieux publishers, Paris, France. Chapter 2. p.18-31, 2007.

62. Patrozou E, **Opal**, SM. "Sepsis and Septicemia" In: Conn's Current Therapy, (Rakel and Bope editors) W.B. Saunders Co., Philadelphia, PA. p. 67-73, 2008.
63. **Opal SM**. Splenectomy and Splenic Dysfunction. In: Infectious Diseases. 3rd Edition. J Cohen, W. Powderly, SM Opal (editors). Mosby, Times-Mirror International Publishers, Edinburgh, UK pp. 1145-1150, 2010.
64. **Opal SM**. Diseases of potential infectious etiology. In: Infectious Diseases. 3rd Edition. J Cohen and W. Powderly (editors). Mosby, Times-Mirror International Publishers, Edinburgh, UK pp. 675-683, 2008.
65. **Opal SM**. Management of a returning traveler from Gabon with a high fever and negative malaria smear. (Practice Point) In: Infectious Diseases. 3rd Edition. J Cohen, W. Powderly, SM Opal (editors). Mosby, Times-Mirror International Publishers, Edinburgh, UK pp. 675-683, 2010.
66. **Opal SM**. Urinary tract infections. In: Intensive Care Medicine, Irwin, Cerra, Rippe (editors), Lippincott, Williams and Wilkins, Philadelphia, PA. 6th edition 2008. pp. 1080-1090
67. Patrozou E, **Opal SM**. What is inflammation, what is sepsis, what is MODS? In: Evidence Based Practice of Critical Care. (Deutschman CS, Neligan PJ ed.) 2010, chapter 24: p151-157.
68. Zaidi N, **Opal SM**. Endotoxin recognition. In: (Ronco E and Kellum J-editors) Critical Care Nephrology 2nd edition. 2009, chapter 148: p 767-773.
69. Patrozou E, **Opal**, SM. "Sepsis and Septicemia" In: Conn's Current Therapy, (Rakel and Bope editors) W.B. Saunders Co., Philadelphia, PA. p. 65-72, 2009.
70. **Opal SM**. "Urinary tract infections in the ICU." In: Intensive Care Medicine, Irwin, Cerra, Rippe (editors), Lippincott, Williams and Wilkins, Philadelphia, PA. 7th edition 2012. pp. 994-1003.
71. **Opal SM**, Pop-Vicas A. Molecular Mechanisms of Antibiotic Resistance in Bacteria. In: Principles and Practice of Infectious Diseases, 7th edition, GL Mandell, JE Bennett and R Dolin (editors), 2009. Elsevier Publishers, Philadelphia, PA. p.279-296.
72. **Opal SM**. A brief history of major milestones in microbiology and immunology. In: A. Artenstein (ed). 2010. Vaccines: A Biography. Chapter 3, pp 31-56. Springer Press, New York, NY
73. **Opal SM**. Endotoxins and other microbial mediators. In: C. Ronco, P. Piccinni, MH. Rosner editors.2010. Contributions in Nephrology. Chapter 2, pp 14-24, Karger AG publishers, Basel CH.
74. **Opal SM**, Telang GH. Cutaneous signs of bacteremia, severe sepsis and septic shock. In: JC Hall and BJ Hall editors 2010. Hall's Manual of Skin as a Marker of Underlying Disease. Chapter 27, pp.407-421. The Peoples Medical Publishing House-USA, Sheldon CT.

75. **Opal SM.** and Kumar A. Influenza infections in critical illness. In: J-L Vincent, E. Abraham, F.A. Moore, P.M. Kochanek, M.P. Fink editors. 2011. Textbook of Critical Care. 6th edition, Elsevier Saunders Publishers, Philadelphia, PA, pp 1061-1067.
76. Delsesto D, **Opal SM.** Future perspectives for novel agents to control pro- and anti-inflammatory responses in sepsis. In: Sepsis- Pro and Anti-Inflammatory Responses. Contributions to Microbiology. Vol 17 H. Herwaldt & Anne Egerten editors. 2011, pp 137-156.

LETTERS, COMMENTARIES AND EDITORIAL REVIEWS

1. Morse PL, **Opal SM.** Adsorption of *Clostridium difficile* antiserum for rapid detection of toxin. (Letter) *Diagnostic Microbiology and Infectious Disease*, 2:169, 1984.
2. Pluss JL, **Opal SM.** Ketoconazole in the treatment of pulmonary *Pseudallescheria boydii* infections. (Letter) *Chest*, 87:843, 1985.
3. **Opal SM.** Book Review: *New England Journal of Medicine*, 315(24): 1558-1559, 1986.
4. **Opal SM.** Book Review. *New England Journal of Medicine*. 316 (11): 697, 1987.
5. Singh V., **Opal SM:** Rocky Mountain Spotted Fever in Rhode Island. *Rhode Island Medical Journal* 71: 155-158, 1988.
6. Victor G, **Opal SM**, Mayer KH Bramley J: Staphylococcal pyomyositis in AIDS. (Letter) *Archives of Internal Medicine* 149:705-706, 1989.
7. Bradburne RM, Etensohn DB, **Opal SM**, McCool DF: Relapse of pneumocystis pneumonia in the upper lobes during aerosol pentamidine prophylaxis. (Letter) *Thorax* 1989;44:1059.
8. Cross AS, **Opal SM**, Group B Streptococcal sepsis. (Letter) *Journal of the American Medical Association*. 268:2651, 1992.
9. Skolnick AA, **Opal SM**, Bone RC, Maldawar LL. Medical New and Perspectives; Researchers try new definitions, New therapies in an effort to solve growing problem of sepsis. *Journal of the American Medical Association*. 269:838-843, 1993.
10. Horn DL, Hewlett D, Alfalla C, Peterson S. **Opal SM.** Limited Tolerance of ofloxacin and pyrazinamide prophylaxis for rifampin-isoniazid-streptomycin-ethambutol (RISE)-resistant tuberculosis infection. *New England Journal of Medicine* 330:1241, 1994.
11. Fisher CJ, **Opal SM.** Tumor necrosis factor in critical illness: (reply). *Critical Care Medicine* 22:1702-1703. 1994.
12. Hunt V, **Opal SM.** Book Review: Manson's Tropical Diseases. *Journal of The American Board of Family Practice* 9:394-395, 1996.

13. Fisher, CJ, Agosti JM, **Opal SM**. Tumor necrosis factor receptor:Fc fusion protein in septic shock. *New England Journal of Medicine*, 335:1067-1069, 1996.
14. **Opal SM**. Differential expression of TNF receptor subtypes in sepsis. (Editorial) *Critical Care Medicine*. 27: 240-241, 1999
15. **Opal SM**. Selenium replacement in severe systemic inflammatory response syndrome. (Editorial) *Critical Care Medicine* 27: 2042-2043, 1999
16. **Opal SM**. Bactericidal/permeability-increasing protein and liver disease. (Editorial) *Shock* 10: 167-168, 1998
17. **Opal SM**. Hemofiltration-absorption systems for the treatment of experimental sepsis: is it possible to remove the evil humors responsible for septic shock? *Critical Care Medicine* 2000; 28:1681-1682.
18. **Opal SM**. New Sepsis drug shows promise in phase III study: the Prowess rhAPC trial. *Pulmonary Reviews* 2002; 7(11):2-4.
19. Artenstein A, Neill MA, **Opal SM**. Bioterrorism and Physicians (letter). *Annals of Internal Medicine* 2002;137:626.
20. **Opal SM**. Low dose steroids in the treatment of septic shock (letter). *Journal of the American Medical Association* 2003; 289:4.
21. **Opal SM**. Clinical trial design and outcomes in patients with severe sepsis: analyzing PROWESS (letter). *Shock* 2004; 21(4):233-4.
22. **Opal SM**. A new way to classify infection in the critically ill. *Pulmonary Reviews* 2004; 9(10):28-29.
23. Wiedermann CJ, Keinecke H-O, Jurs M, **Opal SM**. Baseline severity of sepsis in subjects of the PROWESS and the KyberSept clinical trials of endogenous anticoagulants. *Shock* 2006; 25(6): 657-658.
24. **Opal SM**. Can we RESOLVE the treatment of sepsis? (editorial) *Lancet* 2007;369: 803-804.
25. **Opal SM**. Swine influenza, flu pandemics and critical care medicine. *Critical Care* 2009;13:146
26. **Opal SM**, LaRosa SP. Advances Critical Care 2008: the year in review. *Critical Care* 2009; 13:224 (21/Oct/09)
27. Patrozou E, **Opal SM**. What is Sepsis? SIRS and the inflammatory response to invasive pathogens? In: Evidence Based practice of Critical Care. (Deutschman CS and Neligan PJ editors) Elsevier Publishers, London 2010, chapter 24; p. 151-157.
28. **Opal SM**. Rhode Island Hospital is the only Level 1 trauma center and burn unit in RI. *Intensiv-News* 2009; 5:22-23.

29. Ismail A, Pop-Vicas A. **Opal SM.** Spinal epidural abscess. *Rhode Island Medicine* 2012; 95(1): 20-21.
30. **Opal SM.** Editorial commentary: The Cochrane review of short course antibiotic therapy for hospital-acquired pneumonia in critically-ill patients. *American College of Physicians Journal Club.* 2012; 156(3):3-13.
31. **Opal SM.** Editorial commentary: Surprising cells stymie sepsis. *Science Magazine* 2012; 335; (Jan 12): 3-4
32. Fedson D, **Opal SM.** The H5N1 transmissibility research: A practical response to the current controversy. *Lancet Infectious Diseases* 2012; 12:79-78.